HILDEN, Germany and AARHUS, Denmark, February 2, 2016 /PRNewswire/ --
FDA centers and researchers gain access to QIAGEN's enhanced solutions for applications including microbial and microbiome analysis
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced new partnerships to enhance the profile and expand the use of its market leading bioinformatics solutions for microbiome, metagenomics and other applications.
QIAGEN Bioinformatics signed an agreement with genomics big data company CosmosID, Inc. to allow users of QIAGEN's CLC Genomics Workbench to access and integrate CosmosID's metagenomics analysis platform into their QIAGEN bioinformatics platform. CosmosID's platform allows users to identify and characterize microbial communities from whole genome shotgun data and to determine their relative abundance. The new plug-in expands the range of metagenomic and microbiome applications supported by QIAGEN's microbial genomics solution enabling researchers in fields such as infectious disease, animal health, agriculture, environmental and food safety to use shotgun metagenomics analysis for routine testing employing next-generation sequencing.
Click here for full press release
Investor Relations: John Gilardi Vice President Corporate Communications and Investor Relations +49-2103-29-11711 +1-240-686-2222 Email: firstname.lastname@example.org
SOURCE QIAGEN NV